Compare · MRK vs MYNZ
MRK vs MYNZ
Side-by-side comparison of Merck & Company Inc. (MRK) and Mainz Biomed N.V. (MYNZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and MYNZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $272.41B, about 1458.6x MYNZ ($186.8M).
- Over the past year, MRK is up 32.5% and MYNZ is down 77.4% - MRK leads by 109.9 points.
- MRK has hit the wire 9 times in the past 4 weeks while MYNZ has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 4 for MYNZ).
- Company
- Merck & Company Inc.
- Mainz Biomed N.V.
- Price
- $110.24-1.43%
- $0.83+0.48%
- Market cap
- $272.41B
- $186.8M
- 1M return
- -7.35%
- +1.47%
- 1Y return
- +32.50%
- -77.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 4
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Mainz Biomed N.V.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Latest MRK
- Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
- Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
- FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)
- European Commission Approves Merck's ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
- New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada
- Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
- SEC Form DEFA14A filed by Merck & Company Inc.
- SEC Form DEF 14A filed by Merck & Company Inc.
- Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
- Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
Latest MYNZ
- SEC Form PRE 14A filed by Mainz Biomed N.V.
- Mainz Biomed N.V. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
- SEC Form 4 filed by Director Lazar David E.
- New insider Lazar David E. claimed no ownership of stock in the company (SEC Form 3)
- Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples
- Chief Financial Officer Caragol William J was granted 290,000 units of Ordinary Shares, increasing direct ownership by 372% to 367,899 units (SEC Form 4)
- Director Dreismann Heinrich was granted 45,000 units of Ordinary Shares, increasing direct ownership by 228% to 64,700 units (SEC Form 4)
- Director Tibbitts Gregory J was granted 45,000 units of Ordinary Shares, increasing direct ownership by 414% to 55,875 units (SEC Form 4)
- Chief Executive Officer Baechler Guido was granted 440,000 units of Ordinary Shares, increasing direct ownership by 267% to 605,058 units (SEC Form 4)